“Bavarian Nordic A/S (BAVA), the largest vaccine maker in Denmark, will need to fire hundreds of workers and shut down a factory if it doesn’t receive an order for a smallpox vaccine from the U.S. government by January, the company’s chief executive officer said,” Bloomberg Businessweek reports. “Company officials said they don’t know why the Department of Health and Human Services hasn’t made the order, which they had expected by June,” the news service writes, noting, “The vaccine is meant for people with atopic dermatitis and compromised immune systems, who are at risk of severe adverse reactions to the regular smallpox vaccine.”
US Global Health Policy
In an article on the U.S. Department of Defense webpage, the American Forces Press Service reports on the first U.S. National Strategy for Biosurveillance, issued by the White House “to quickly detect a range of global health and security hazards.” According to the article, “the Defense Department has a running start in implementing the new plan, a senior defense official said,” and “many of the activities described in the strategy are ongoing at DOD.” “So much of what we’re doing is integrating the efforts and working hard on the overlap between global security and global health, in what [President Barack Obama] refers to as global health security,” said Andrew Weber, assistant secretary of defense for nuclear, chemical and biological defense programs, the news service writes (Pellerin, 8/22).
“The United States announced Thursday it would hike its humanitarian aid to Syria, adding another $12 million to provide food, water, medicine and other necessities for battered and displaced people” affected by violence in the Syrian conflict, the Los Angeles Times blog “World Now” reports. “The increase approved by the Obama administration brings American humanitarian assistance in Syria to more than $76 million, including $27.5 million to the World Food Programme [WFP], roughly $18 million for the United Nations refugee agency and the rest split among other U.N. funds and non-profit groups,” the blog writes (Alpert, 8/2).
Diagnostics company Cepheid on Monday signed deals with PEPFAR, USAID, UNITAID, and the Bill & Melinda Gates Foundation to immediately reduce the price of its Xpert MTB/RIF test kit for its GeneXpert tuberculosis (TB) diagnostic system in 145 countries, Reuters reports. “The agreements will see the test sold for $9.98, down from its current price of $16.86 per test,” the news service writes, adding, “Cepheid said the Bill & Melinda Gates Foundation will make an initial payment of $3.5 million to make the test immediately available at the lower price” (Ail, 8/6).
With incentives to find new antibiotics signed into U.S. law last month, “multiple players are vying for the lead in the [multi-drug resistant tuberculosis (MDR-TB)] drug development niche,” Nature Medicine reports. “The fifth reauthorization of the U.S. Prescription Drug User Fee Act (PDUFA), signed into law on 9 July, includes a subsection called the Generating Antibiotic Incentives Now (GAIN) Act that aims to spur development of antibiotics for drug-resistant bacteria, including MDR-TB,” the news service writes, noting, “Drug makers that ask for approval of medicines to treat these pathogens will receive priority review, as well as five additional years of market exclusivity and fast-track status.” Currently, MDR-TB treatment “involves a bevy of regular tuberculosis medicines that, in many cases, must be administered for as long as two years or more … [and] don’t always work,” Nature Medicine states, adding, “The hope is that new medicines will shorten treatment times and improve cure rates.” The article discusses several medicines that are in different phases of research (Willyard, 8/6).
“During the recent [XIX International AIDS Conference (AIDS 2012)] in Washington, D.C., exciting breakthroughs in HIV prevention, treatment, and care — even a possible cure — took center stage,” but, “despite recent advances, many men and women remain at risk of HIV as a result of structural issues that fuel and have an impact on the epidemic,” Molly Fitzgerald, technical advisor for AIDSTAR-One, writes in this post in USAID’s “Impact Blog.” “Addressing gender inequality, poverty, stigma, and other social, economic, cultural, and legal factors is necessary to create an ‘enabling environment’ for these promising biomedical and behavioral interventions,” she continues, noting, “There is increasing agreement worldwide that structural issues are too often overlooked where HIV prevalence remains high” (8/16).
As part of its monthly series Stories Behind the Statistics, “guest edited by FHI 360 on behalf of USAID’S IYWG, which provides technical leadership to improve the reproductive and sexual health of young people,” the Bill & Melinda Gates Foundation’s “Impatient Optimists” blog features a story by Gaj Bahadur Gurung, program coordinator for the National Federation of Women Living with HIV and AIDS in Nepal, who discusses the impact of adolescent pregnancy on girls and young women in South Asia. He writes, “Policies and programs must both help prevent early and unintended pregnancy (for married and unmarried women) and mitigate the negative consequences for girls who do become pregnant. Programs should provide young women access to, control over, and informed choice of their sexual and maternal health services” (8/3).
On the first stop of a 10-day tour of Africa, Secretary of State Hillary Clinton stopped at the Phillipe Maguilen Senghor Health Center in Dakar, Senegal, where Awa Marie Coll-Seck, the country’s minister of health, “explained to Secretary Clinton how these operational centers dramatically improve maternal and child health,” according to a post in USAID’s “IMPACTblog.” Coll-Seck “also noted that USAID-supported distribution of insecticide impregnated mosquito nets across the country had drastically reduced the incidence of malaria,” according to the blog, which adds that Clinton “was pleased to hear that the United States is playing a key role in helping meet one of its biggest challenges: decentralizing services so they are available at the village level throughout the country.” In an address several hours later, “Clinton invoked the Senghor center … saying she was highly impressed by the integrated nature of the facility” and that “[i]t was a successful model she hoped could be duplicated throughout Senegal and the entire West African region” (Taylor, 8/1).
The XIX International AIDS Conference (AIDS 2012) that took place last week in Washington, D.C., “ignited momentum to shift from ‘fighting AIDS’ to ‘ending AIDS,’” Mohga Kamal-Yanni, senior health adviser at Oxfam International, and Urvarshi Rajcoomer, policy and advocacy adviser at Oxfam in South Africa, write in a Mail & Guardian opinion piece. “Oxfam believes investing in health systems such as infrastructure and health worker, drug supply chain and health information systems, is a critical prerequisite to ending AIDS,” they write. However, “to make this a reality,” pharmaceutical companies, donor governments, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the World Bank “must now do their part,” they continue.
In this post in Huffington Post’s “Impact” blog, Deborah Derrick, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, examines “the success of U.S. efforts to promote better global health through support for [PEPFAR] and the Global Fund to Fight AIDS, Tuberculosis and Malaria.” She highlights U.S. Secretary of State Hillary Clinton’s recent trip to Africa, writing that Clinton’s “encouraging words” at the Reach Out Mbuya health center in Uganda reinforced U.S. commitment to an AIDS-free generation. She notes both PEPFAR and the Global Fund have supported the center and adds that “through hundreds of similar local programs all over the world, the Global Fund provides treatment to 3.6 million people who are HIV-positive.”